MedTrace Logo

Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC

NCT04549428 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-11-18

No results posted yet for this study

Summary

Multicentre, phase II, open-label, single-arm study evaluating the preliminary efficacy, safety and tolerability of atezolizumab in association with palliative radiotherapy in adult patients diagnosed with advanced (stage IV) NSCLC, irrespective of PD-L1 status, and who have oligoprogressed to both immunotherapy with an anti PD-1 agent (e.g., pembrolizumab or nivolumab) and 1 line of chemotherapy.

Conditions

  • NSCLC Stage IV

Interventions

DRUG

Atezolizumab

Intravenous infusion every 21 days, until disease progression, intolerance or loss of clinical benefit.

Sponsors & Collaborators

  • Ente Ospedaliero Cantonale, Bellinzona

    collaborator OTHER

  • Istituto Cantonale di Patologia

    collaborator OTHER

  • Clinical Trial Unit Ente Ospedaliero Cantonale

    collaborator OTHER

  • Oncology Institute of Southern Switzerland

    lead OTHER

Principal Investigators

  • Francesco Martucci, MD · Oncology Institute of Southern Switzerland

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2023-01-23
Completion
2025-05-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04549428 on ClinicalTrials.gov